PE20090975A1 - Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma - Google Patents

Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma

Info

Publication number
PE20090975A1
PE20090975A1 PE2008001813A PE2008001813A PE20090975A1 PE 20090975 A1 PE20090975 A1 PE 20090975A1 PE 2008001813 A PE2008001813 A PE 2008001813A PE 2008001813 A PE2008001813 A PE 2008001813A PE 20090975 A1 PE20090975 A1 PE 20090975A1
Authority
PE
Peru
Prior art keywords
antibody
type
combination therapy
proteasome inhibitor
refers
Prior art date
Application number
PE2008001813A
Other languages
English (en)
Inventor
Georg Fertig
Thomas Friess
Christian Kelin
Pablo Umana
Original Assignee
Hoffmann La Roche
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38973774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090975(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Glycart Biotechnology Ag filed Critical Hoffmann La Roche
Publication of PE20090975A1 publication Critical patent/PE20090975A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN ANTICUERPO ANTI-CD20 DE TIPO II TAL COMO ANTICUERPO B.Ly1 HUMANIZADO, DONDE EL 40% O MAS OLIGOSACARIDOS DE LA REGION Fc DE DICHO ANTICUERPO SON NO FUCOSILADOS; Y B) UN INHIBIDOR DE PROTEASOMA TAL COMO BORTEZOMIB QUE TIENE UNA IC50 DE 5uM O MENOS. SE REFIERE TAMBIEN A UN KIT PARA EL TRATAMIENTO DE COMBINACION. DICHA COMPOSICION ES UNA COMBINACION SINERGICA UTIL EN EL TRATAMIENTO DEL CANCER QUE EXPRESA EL CD20 TAL COMO LINFOMA NO HODKING DE CELULAS B
PE2008001813A 2007-10-24 2008-10-22 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma PE20090975A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07020820 2007-10-24

Publications (1)

Publication Number Publication Date
PE20090975A1 true PE20090975A1 (es) 2009-07-13

Family

ID=38973774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001813A PE20090975A1 (es) 2007-10-24 2008-10-22 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma

Country Status (16)

Country Link
US (4) US20090110688A1 (es)
EP (1) EP2205318B1 (es)
JP (1) JP5469073B2 (es)
KR (1) KR101280733B1 (es)
AR (1) AR071733A1 (es)
AU (1) AU2008315926A1 (es)
CA (1) CA2702962C (es)
CL (1) CL2008003122A1 (es)
ES (1) ES2527775T3 (es)
IL (1) IL205025A0 (es)
MX (1) MX2010004164A (es)
PE (1) PE20090975A1 (es)
RU (1) RU2520757C2 (es)
TW (1) TW200927762A (es)
WO (1) WO2009053038A2 (es)
ZA (1) ZA201002575B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202008722QA (en) * 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
JP2013501741A (ja) * 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011060179A1 (en) * 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
MX342590B (es) * 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
TW201208703A (en) * 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
JP2014507384A (ja) * 2010-12-16 2014-03-27 ロシュ グリクアート アーゲー Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法
WO2012135528A2 (en) * 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
US9856534B2 (en) 2011-04-29 2018-01-02 Emory University Selecting use of proteasome inhibitors based on NF-κB2 sequence
CN104204797B (zh) * 2012-01-24 2017-05-31 米伦纽姆医药公司 治疗癌症的方法
EP2812338A4 (en) * 2012-01-24 2015-09-23 Millennium Pharm Inc METHOD FOR THE TREATMENT OF NASOPHARYNGEAL CANCER
JP6511609B2 (ja) 2013-03-13 2019-05-22 ジェネンテック， インコーポレイテッド 抗体製剤
AU2015318001B2 (en) 2014-09-15 2021-03-25 Genentech, Inc. Antibody formulations
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1071700B1 (en) * 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO2001034194A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
SG10202008722QA (en) * 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
EP1863513A2 (en) * 2005-03-11 2007-12-12 The University of North Carolina at Chapel Hill Potent and specific immunoproteasome inhibitors
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
AR055137A1 (es) * 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada

Also Published As

Publication number Publication date
RU2010120724A (ru) 2012-05-20
JP2011500741A (ja) 2011-01-06
US20160000912A1 (en) 2016-01-07
WO2009053038A2 (en) 2009-04-30
EP2205318A2 (en) 2010-07-14
AR071733A1 (es) 2010-07-14
MX2010004164A (es) 2010-08-04
JP5469073B2 (ja) 2014-04-09
IL205025A0 (en) 2010-11-30
CA2702962C (en) 2016-10-25
KR101280733B1 (ko) 2013-07-02
AU2008315926A1 (en) 2009-04-30
WO2009053038A3 (en) 2009-06-25
EP2205318B1 (en) 2014-11-19
CL2008003122A1 (es) 2009-10-16
ZA201002575B (en) 2011-04-28
US20110200598A1 (en) 2011-08-18
CN102083499A (zh) 2011-06-01
ES2527775T3 (es) 2015-01-29
CA2702962A1 (en) 2009-04-30
KR20100068292A (ko) 2010-06-22
US20090110688A1 (en) 2009-04-30
RU2520757C2 (ru) 2014-06-27
US20120219549A1 (en) 2012-08-30
TW200927762A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
PE20090975A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma
PE20091821A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
CL2016002585A1 (es) Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373)
PE20171241A1 (es) Terapias de combinacion para el tratamiento de canceres
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
PE20080911A1 (es) Anticuerpo anti-vegf
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CO6781506A2 (es) Uso del agonista de receptor tipo toll para el tratamiento del cáncer
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
EA201390756A1 (ru) Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
CL2011001255A1 (es) Combinaciones farmaceutica que comprende un anticuerpo que reconoce especificamente cd38 y al menos vincristina; y uso del anticuerpo que reconoce especificamente cd38 para el tratamiento del cancer.
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
CR11723A (es) Agente para tratar enfermedad
AR101740A1 (es) Terapia de combinación y composiciones
EA201290381A1 (ru) Применение содержащего тритерпены олеогеля для заживления ран

Legal Events

Date Code Title Description
FA Abandonment or withdrawal